Literature DB >> 2790041

Platelet-activating factor induces the production of leukotrienes by human monocytes.

J Fauler1, G Sielhorst, J C Frölich.   

Abstract

The aim of this study was to evaluate the role of platelet-activating factor (PAF) as a stimulator of leukotriene production by human monocytes. The production of leukotrienes was time- and concentration-dependent. Release of leukotrienes was half-maximal after 2 min and reached a maximum after 10 min. At a concentration of 10(-8) M, PAF induced the production of 0.14 +/- 0.01 ng LTB4/10(6) cells (mean +/- S.E., n = 8). At concentrations of 10(-6) M, PAF induced the production of 1.0 +/- 0.04 ng LTB4 and 0.22 +/- 0.03 ng peptidoleukotrienes (mean +/- S.E., n = 16). There was no metabolism of LTB4 as judged from stability of [3H]LTB4 added to the incubations. LTC4 was slowly metabolized by human monocytes to LTD4 and LTE4. The two specific PAF-receptor antagonists BN 52021 and WEB 2086 in concentrations of 10(-4) and 10(-6) M, respectively, inhibited the PAF (10(-6) M) stimulated LTB4 production completely. In this study, we demonstrate that nanomolar concentrations of PAF can stimulate the production of LTB4 and peptidoleukotrienes in human monocytes by a receptor-mediated mechanism.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2790041     DOI: 10.1016/0167-4889(89)90131-6

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  3 in total

Review 1.  PAF. A review of its effects, antagonists and possible future clinical implications (Part II).

Authors:  M Koltai; D Hosford; P Guinot; A Esanu; P Braquet
Journal:  Drugs       Date:  1991-08       Impact factor: 9.546

2.  Effect of platelet activating factor (PAF) on the migration of human lymphocytes.

Authors:  R G McFadden; M A Bishop; A N Caveney; L J Fraher
Journal:  Thorax       Date:  1995-03       Impact factor: 9.139

3.  Inhaled budesonide fails to inhibit the PAF-induced increase in plasma leukotriene B4 in man.

Authors:  M M Nieminen; E K Moilanen; M O Koskinen; J I Karvonen; L Tuomisto; T J Metsä-Ketelä; H Vapaatalo
Journal:  Br J Clin Pharmacol       Date:  1992-06       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.